JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Ocular Therapeutix Inc

Avatud

SektorTervishoid

11.35 -5.81

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10.53

Max

12.32

Põhinäitajad

By Trading Economics

Sissetulek

-16M

-64M

Müük

-6.4M

11M

Kasumimarginaal

-602.342

Töötajad

274

EBITDA

-20M

-64M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+46.31% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

600M

1.9B

Eelmine avamishind

17.16

Eelmine sulgemishind

11.35

Uudiste sentiment

By Acuity

31%

69%

98 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Ocular Therapeutix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 21:42 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4. aug 2025, 21:21 UTC

Tulu
Suurimad hinnamuutused turgudel

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. aug 2025, 20:45 UTC

Tulu

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. aug 2025, 19:15 UTC

Suurimad hinnamuutused turgudel

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4. aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4. aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4. aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4. aug 2025, 21:30 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. aug 2025, 21:21 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4. aug 2025, 21:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss $938M >RIG

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss/Shr $1.06 >RIG

4. aug 2025, 20:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4. aug 2025, 20:15 UTC

Tulu

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. aug 2025, 20:13 UTC

Tulu

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. aug 2025, 20:09 UTC

Tulu

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4. aug 2025, 20:06 UTC

Tulu

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4. aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4. aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4. aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4. aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ocular Therapeutix Inc Prognoos

Hinnasiht

By TipRanks

46.31% tõus

12 kuu keskmine prognoos

Keskmine 17.44 USD  46.31%

Kõrge 22 USD

Madal 14 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Ocular Therapeutix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.97 / 7.62Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

98 / 374 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.